Search
Back

Neratinib Maleate

CAS 698387-09-6
Neratinib Maleate

General Information

Neratinib, the active ingredient in neratinib maleate, belongs to the class of molecules termed antineoplastic agents, which inhibit the maturation, growth or spread of tumor cells. It significantly reduces the risk of recurrence of breast cancer in post-surgery adult patients who have been treated with trastuzumab (herceptin) for early stage HER2-overexpressed breast cancer.  In clinical studies, patients taking Neratinib showed a 33% reduction in the risk of recurrence within two years.


About the API

Technology Synthetic
Therapeutic category Oncology
Available formulations Oral Solid
Regulations
  • Japan DMF
  • Korea DMF
  • US DMF

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.